BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax is a BH3 mimetic and the only FDA-approved BCL-2 inhibitor for treatment of CLL, SLL, and AML in combination with DNA methyltransferase inhibitors or low-dose cytarabine [69].